Company Active LTD

Company profile

Abtrace Limited

Abtrace - Transforming Clinical Decisions through Data

Transforming Clinical Decisions through Data

CRN
11535661
Founded
2018
Age
7

Overview

Legal name
ABTRACE LIMITED
Region
London
Registered address
6TH FLOOR, MANFIELD HOUSE
1 SOUTHAMPTON STREET
LONDON
ENGLAND
WC2R 0LR
Insolvency history
No

Latest accounts

Financial period: 1 Sep 2023 to 31 Aug 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
23

Company events

Reference milestones and recent Companies House filing stream events.

6 events
04 Sep
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Aug
2026

Accounts due

Accounts Due

Next accounts due date

21 Aug
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

02 Sep
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQzNDE2NDk5MmFkaXF6a2N4

Published 02 Sep 2024 15:13

31 Aug
2024

Accounts filed

Accounts

Last accounts made up date

24 Aug
2018

Incorporated

Inception

Company registered at Companies House

Public funding

7 awards
First funded
2020
Funded years
2020, 2021, 2022, 2023, 2024
Age at first award
2 years

Projects

2024 Collaborative R&D Lead participant

AutoPharmacist: Automated Medication Monitoring System in Primary Care

1 Mar 2024 to 31 Aug 2025

Awarded
£348,845
Total cost £498,350

**BACKGROUND** Every year over **40% of the UK population take 770 million regular medications** to manage and prevent disease. Their General Practitioner (GP) has the vast task of ensuring they are on the right medications, **with 15% of the population taking more than 5 medications regularly, and 25% having multiple long-term conditions.** **PROBLEM** I...

2023 Collaborative R&D Lead participant

Large Language Models based algorithms for personalised cancer detection

1 Nov 2023 to 31 Jul 2025

Awarded
£428,774
Total cost £612,534

More than a thousand patients are diagnosed with cancer daily in the UK - **1 in 2 people will get this diagnosis in their lifetime**. Many cancers being diagnosed at an advanced stage when treatments are less effective. The UK has poorer cancer survival rates compared to other high-income countries. The long-term plan aims to be diagnosing 75% of cancer ...

2023 Collaborative R&D Lead participant

MonitorABLE - AI based Remote Patient Deterioration Detection Platform

1 Aug 2023 to 31 Jan 2025

Awarded
£348,530
Total cost £497,900

The **NHS and health systems around the world are under great pressure** with rising A&E attendances and hospital admissions alongside **budgetary pressures,** backlogs and an increasingly **ageing, less healthy population**. Hospitals are overflowing. However, **1 out of 5** emergency admissions are **avoidable** and responsible for taking up 13% of all ...

2022 Collaborative R&D Lead participant

Clinical Intelligent Automation of Preventative Care

1 Oct 2022 to 31 Mar 2024

Awarded
£349,934
Total cost £499,905

In addition to _treating_ disease, healthcare staff in primary care try to _prevent_ disease. Patients who meet clinical risk criteria can benefit from actions like starting medications before they develop a disease. These _preventative interventions_ reduce the risk of disease or delay it. **40% of all yearly deaths are thought to be due to preventable c...

2021 Collaborative R&D Lead participant

Recovery from Covid: Using advanced AI and Natural Language Processing to accurately and automatically predict hospital occupancy

1 Dec 2021 to 31 Jan 2022

Awarded
£57,595
Total cost £57,595

**Challenge to address** At every stage of the Patient inflow and outflow process within the NHS, there are delays which impact on patient care, staff, hospital resources and efficiency. The vast majority of delays are attributable to hospitals and staff not having access to information or that information being incomplete or out-of-date, which in turn le...

2021 Collaborative R&D Lead participant

CanDetect: AI based early cancer detection using unstructured data

1 Jul 2021 to 30 Jun 2023

Awarded
£692,438
Total cost £989,197

UK cancer survival rates lag behind other developed countries(1), up to 10,000 excess deaths occur annually in comparison(2). Delayed diagnosis is thought to contribute to this(3). Currently nearly half of all cancers are diagnosed at a late stage(4). Approximately 20% of patients see their GP 3 or more times before their cancer diagnosis(7) with approxim...

2020 Collaborative R&D Lead participant

Using advanced AI and Natural Language Processing to accurately and automatically predict hospital length of stay, related patient-NHS resource requirements and improve discharge efficiency

1 Nov 2020 to 30 Apr 2022

Awarded
£395,711
Total cost £494,639

**Challenge to address** At every stage of the Patient inflow and outflow process within the NHS, there are delays which impact on patient care, staff, hospital resources and efficiency. The vast majority of delays are attributable to hospitals and staff not having access to information or that information being incomplete or out-of-date, which in turn le...

Product types

Collaborative R&D